Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) will release its second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company will host a conference call the same day at 4:30 p.m. Eastern Time to review the results and provide corporate updates.
Investors can join by phone using U.S. and international dial-in numbers or listen via a live webcast on Viking’s investor relations website. A telephone replay will be available until August 5, 2026, and a webcast archive will remain online for 30 days.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report: VKTX -5.15% in the Jul 23 session
In the Jul 23 session, VKTX declined 5.15%, reflecting a notable negative market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | earnings date | Neutral | -4.2% | Scheduled first-quarter 2026 results and a 4:30 p.m. Eastern conference call |
| Feb 04 | earnings date | Neutral | -11.1% | Scheduled fourth-quarter and year-end 2025 results with a conference call |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Both tag-matched earnings-date announcements were followed by negative 24-hour reactions, averaging -7.65%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 29, 2026. To participate in the conference call, please dial (844) 850-0543 from the
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biotechnology company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, and a Phase 1 study designed to evaluate maintenance dosing strategies to support long-term weight management. Viking's pipeline also includes additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july-29-2026-302831513.html
SOURCE Viking Therapeutics, Inc.